Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity - PubMed (original) (raw)
Controlled Clinical Trial
doi: 10.1210/jc.2006-1610. Epub 2006 Dec 27.
Affiliations
- PMID: 17192294
- DOI: 10.1210/jc.2006-1610
Controlled Clinical Trial
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity
Steven D Chernausek et al. J Clin Endocrinol Metab. 2007 Mar.
Abstract
Context: Children with severe IGF-I deficiency due to congenital or acquired defects in GH action have short stature that cannot be remedied by GH treatment.
Objectives: The objective of the study was to examine the long-term efficacy and safety of recombinant human IGF-I (rhIGF-I) therapy for short children with severe IGF-I deficiency.
Design: Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Setting: The study was conducted at general clinical research centers and with collaborating endocrinologists.
Subjects: Entry criteria included: age older than 2 yr, sd scores for height and circulating IGF-I concentration less than -2 for age and sex, and evidence of resistance to GH.
Intervention: rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Main outcome measures: Height velocity, skeletal maturation, and adverse events were measured.
Results: Height velocity increased from 2.8 cm/yr on average at baseline to 8.0 cm/yr during the first year of treatment (P < 0.0001) and was dependent on the dose administered. Height velocities were lower during subsequent years but remained above baseline for up to 8 yr. The most common adverse event was hypoglycemia, which was observed both before and during therapy. It was reported by 49% of treated subjects. The next most common adverse events were injection site lipohypertrophy (32%) and tonsillar/adenoidal hypertrophy (22%).
Conclusions: Treatment with rhIGF-I stimulates linear growth in children with severe IGF-I deficiency due to GH insensitivity. Adverse events are common but are rarely of sufficient severity to interrupt or modify treatment.
Comment in
- Defining the role of IGF-I therapy for short children.
Levitsky LL. Levitsky LL. J Clin Endocrinol Metab. 2007 Mar;92(3):813-4. doi: 10.1210/jc.2007-0087. J Clin Endocrinol Metab. 2007. PMID: 17341577 No abstract available.
Similar articles
- Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM; MS301 Study Group. Midyett LK, et al. J Clin Endocrinol Metab. 2010 Feb;95(2):611-9. doi: 10.1210/jc.2009-0570. Epub 2009 Oct 30. J Clin Endocrinol Metab. 2010. PMID: 19880790 Clinical Trial. - Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO. Camacho-Hübner C, et al. J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53. doi: 10.1210/jc.2005-1017. Epub 2006 Jan 10. J Clin Endocrinol Metab. 2006. PMID: 16403822 Clinical Trial. - Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF. Kemp SF. BioDrugs. 2009;23(3):155-63. doi: 10.2165/00063030-200923030-00002. BioDrugs. 2009. PMID: 19627167 Review. - Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.
Backeljauw PF, Underwood LE; GHIS Collaborative Group. Growth hormone insensitivity syndrome. Backeljauw PF, et al. J Clin Endocrinol Metab. 2001 Apr;86(4):1504-10. doi: 10.1210/jcem.86.4.7381. J Clin Endocrinol Metab. 2001. PMID: 11297575 - Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
[No authors listed] [No authors listed] Drugs R D. 2005;6(2):120-7. doi: 10.2165/00126839-200506020-00008. Drugs R D. 2005. PMID: 15777106 Review.
Cited by
- QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction.
Maharaj AV, Ishida M, Rybak A, Elfeky R, Andrews A, Joshi A, Elmslie F, Joensuu A, Kantojärvi K, Jia RY, Perry JRB, O'Toole EA, McGuffin LJ, Hwa V, Storr HL. Maharaj AV, et al. Nat Commun. 2024 Sep 28;15(1):8420. doi: 10.1038/s41467-024-52587-w. Nat Commun. 2024. PMID: 39341815 Free PMC article. - The Treatment of Growth Disorders in Childhood and Adolescence.
Woelfle J, Schnabel D, Binder G. Woelfle J, et al. Dtsch Arztebl Int. 2024 Feb 9;121(3):96-106. doi: 10.3238/arztebl.m2023.0247. Dtsch Arztebl Int. 2024. PMID: 38051162 Free PMC article. Review. - A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.
Niazi SK. Niazi SK. Pharmaceuticals (Basel). 2023 Nov 2;16(11):1556. doi: 10.3390/ph16111556. Pharmaceuticals (Basel). 2023. PMID: 38004421 Free PMC article. Review. - Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective.
Backeljauw PF, Andrews M, Bang P, Dalle Molle L, Deal CL, Harvey J, Langham S, Petriczko E, Polak M, Storr HL, Dattani MT. Backeljauw PF, et al. Orphanet J Rare Dis. 2023 Oct 7;18(1):312. doi: 10.1186/s13023-023-02928-7. Orphanet J Rare Dis. 2023. PMID: 37805563 Free PMC article. Review. - The metabolic effects of resumption of a high fat diet after weight loss are sex dependent in mice.
Guerra-Cantera S, Frago LM, Jiménez-Hernaiz M, Collado-Pérez R, Canelles S, Ros P, García-Piqueras J, Pérez-Nadador I, Barrios V, Argente J, Chowen JA. Guerra-Cantera S, et al. Sci Rep. 2023 Aug 14;13(1):13227. doi: 10.1038/s41598-023-40514-w. Sci Rep. 2023. PMID: 37580448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources